Johnson & Johnson has agreed to an estimated US$5.5 billion (about A$7.9 billion) settlement covering approximately 76,000 existing US claims alleging that its talc-based baby powder and other products caused ovarian cancer.
The proposal could end most of the company’s remaining ovarian-talc litigation after more than a decade. However, it is not final: at least 95% of eligible claimants in federal and state courts must accept the agreement.
Who qualifies for the J&J settlement?
The agreement covers existing ovarian-cancer claims, including cases consolidated in federal multidistrict litigation in New Jersey and related state-court lawsuits.
Using Johnson’s Baby Powder does not automatically make someone eligible. Qualification will depend on an existing claim, an eligible diagnosis and supporting documentation required by the final settlement terms.
The proposal does not cover future lawsuits. Most claims alleging that asbestos in talc caused mesothelioma have been handled separately.
How much could each claimant receive?
No standard individual payout has been announced. The agreement assigns specific values to qualifying claims, meaning US$5.5 billion will not simply be divided equally among 76,000 people.
Payments may vary according to the settlement’s valuation rules. Legal fees, expenses and other deductions may also affect the amount a claimant receives.
Attorney Chris Seeger, who represents about 2,500 claimants and helped negotiate the deal, said J&J could ultimately pay US$7 billion or more. The settlement does not place a fixed cap on the total payout if more qualifying claims participate.
When will payments begin?
J&J expects to pay up to US$3 billion in 2027, followed by further payments beginning in 2028. No universal payment date has been announced because claims must first be reviewed and the 95% participation threshold must be reached.
Lawyers involved in the negotiations say eligible existing claims could be paid within approximately 18 months. That is faster than an earlier bankruptcy proposal that would have distributed payments over more than a decade.
Why is 95% approval required?
The high acceptance threshold is intended to provide broad closure for existing ovarian-cancer litigation. If fewer than 95% of eligible claimants participate, J&J may be able to withdraw and unresolved cases could continue in court.
Claimants must weigh the proposed payment against the cost, delay and uncertainty of continuing an individual lawsuit. Accepting compensation would generally mean giving up the right to pursue the covered claim separately.
Why did Johnson & Johnson settle now?
The deal followed several favourable developments for J&J, including trial victories and rulings challenging evidence presented by plaintiffs. Shortly before the agreement, a federal judge questioned whether individual claimants could prove that talc specifically caused their ovarian cancer.
J&J litigation vice-president Erik Haas called the claims “meritless” and said the company believed it would ultimately prevail. Its position is available through J&J’s official corporate announcements.
The settlement is not an admission of liability. J&J continues to maintain that its talc products were safe and did not contain asbestos.
What happened in earlier talc cases?
J&J has a mixed trial record. It won some cases and had other verdicts reduced or overturned on appeal. In one major case, 22 women who alleged that baby powder caused their ovarian cancer initially received a multibillion-dollar jury award.
The company also tried three times to resolve the litigation through subsidiary bankruptcies using a strategy known as the “Texas two-step.” Courts dismissed each attempt, and the litigation resumed in March 2025 after being paused for more than three years.
The new agreement operates through the regular civil-litigation system and applies only to existing claims. Lawyers say excluding future lawsuits made more money available for current claimants and shortened the payment period.
Read More:
Is talc-based baby powder still sold?
J&J stopped selling talc-based baby powder in the United States and Canada in 2020 and ended global sales in 2023. The company replaced talc with cornstarch.
In 2024, the World Health Organization’s cancer research agency classified talc as “probably carcinogenic to humans.” That hazard classification does not establish that talc caused cancer in every individual case.
Does the settlement cover Australians?
No automatic entitlement has been announced for Australians. The A$7.9 billion amount is a currency conversion, not an Australian settlement fund. Australia has separate legal proceedings involving allegations about talc products.
Eligibility requirements differ between settlements. Readers can compare this process with the rules for Canadians filing claims in the Silk and Great Value recall settlement, where location and filing deadlines determine access to compensation.
The pharmaceutical industry is facing other major legal disputes, including Novo Nordisk’s lawsuit against Eli Lilly over weight-loss drug advertising. Existing J&J claimants should obtain case-specific information from their lawyers rather than relying on unofficial settlement websites.
Make Swikblog your go-to source on Google for reliable updates, smart insights, and daily trends.
